Between 2001 and 2006 six human clinical trials with the hexadecapeptide AOD9604 have been performed, 893 healthy, in all but one study, clinically obese adults participated in these studies and are the basis of this safety evaluation. The details of the individual studies are listed in supplementary data. The first 3 studies were dose-escalating studies investigating the acute effects of various dosages and two application routes (i.v. and oral) in healthy or obese male subjects. These single dose studies were followed by a 7-day multiple dose study (METAOD004) as well as two long-term clinical trials (METAOD005 and METAOD006) where the safety and tolerability of chronic oral treatment with AOD9604 was investigated.

As in the previous study there were no clinically relevant changes observed in safety laboratory parameters 24 hours following administration of AOD9604 or placebo. Similarly, there were no clinically relevant changes in vital signs (blood pressure, radial pulse rate and temperature) or ECGs recorded at any of the scheduled time points up to 24 hours post dose. There were no significant changes in glucose or IGF-1 levels following AOD9604 treatment compared with placebo.
Perhaps. As Dr Larkins weighs in: "It's a different kind of chemical and physiological manipulation that goes way beyond what I'd call conventional hormone therapy. It's the next stage of technology that's come along to try and help people enjoy quality of life." A stage with an effect apparently significant enough to risk a professional athletic career for.
AOD9604 is a peptide fragment of the C-terminus of human growth hormone (Tyr-hGH177-191). It is prepared by solid phase peptide synthesis and contains an additional tyrosine residue at the N-terminal end that stabilizes the peptide. Investigation on the secondary structure of AOD9604 showed similarities to the homologous region in the naturally occurring hGH molecule [19]. Animal experiments confirmed the fat reducing potential of AOD9604, which seems to act directly on fat metabolism without influencing appetite. In genetically obese strains of rats and mice, AOD9604 was shown to affect body weight reduction, stimulation of lipolysis and inhibition of lipogenesis. Adverse effects, as seen in similar studies using intact hGH [18, 20, 21], were not observed with AOD9604 supplementation.

There were no significant changes in IGF-1 values observed during 24 hours following any AOD9604 dose compared with placebo. No significant differences in glucose levels were observed following AOD9604 administration compared with placebo with the exception of one isolated time point (8% increase 12 hour post treatment in one subject receiving 54 mg AOD09604). There were no clinically significant observable trends in vital signs, physical examinations, abnormalities noted in the ECG measurements, or findings in the safety-related laboratory tests throughout the study.
IGF-1 is so named because of its close resemblance to insulin. Because IGF-1 is so similar to insulin, it interacts with insulin receptors on the surface of your cells, produces some of the same effects as insulin and even magnifies the effect of insulin. For example, one primary effect of both excess insulin and excess IGF-1 is hypoglycemia (low blood glucose). When you workout for a long time (longer than about one hour) your liver increases its release of IGF-binding protein (IGFBP-3) to prevent the onset of hypoglycemia that would otherwise happen as a result of the increased release of IGF-1 that occurs during training.
There were concerns regarding the number of contraindications and precautions and whether consumers would be able to interpret these appropriately without a requirement for pharmacist advice. There were concerns regarding gastro-intestinal, renal and other adverse effects related to the potential interactions of ibuprofen and paracetamol. Also raised were concerns regarding the potential for paracetamol overdose.
For Growth Hormone (GH) to perform its anabolic (muscle building) affects it requires the presence of the body's most anabolic hormone: insulin. This is in contrast to GH related fat loss which requires insulin to be absent. However, since GHRP and fast-acting GHRH (Growth Hormone Releasing Hormone) products (i.e. Modified GRF 1-29) still need time to stimulate the body to release GH from the pituitary gland, the insulin spike must come after the injection and not before, otherwise the GH release will be blunted.
Growth hormone releasing peptide (GHRP) 2 is a type of peptide therapeutic that mimics the effects of ghrelin, the “hunger hormone”. Ghrelin is a hormone that helps regulate appetite as well as energy distribution and rate of use, or metabolism. In the 1980’s, ghrelin was discovered to be the body’s natural ligand (or binding molecule) of the GHRP receptor in the anterior pituitary. This was a significant discovery, as it highlighted the role of ghrelin in hGH secretion and growth regulation. Modern biotechnology has used this knowledge to develop peptides that can be administered to mimic ghrelin’s hGH stimulation, but in a more targeted fashion. GHRP 2 is one such peptide, stimulating hGH secretion by 7-15 times, increasing appetite and meal initiation, while also decreasing fat mass and cholesterol. GHRP 2 is ideal for patients who are hypercatabolic, due to critical illness, cancer, AIDS, etc. It should be noted that GHRP 2 can also increase levels of prolactin, aldosterone, and cortisol.
Mean gross morphological and histopathological scores in Group 1 were significantly higher than those in Groups 2, 3, and 4 (p<0.05). Mean gross morphological and histopathological scores in Group 4 were significantly lower than those in Groups 2 and 3 (p<0.05). However, there are no differences between the mean gross morphological and histopathological scores of Groups 2 and 3 (Figures 4 and 5).
Application would result in all current OTC paracetamol/ phenylephrine products being up-scheduled to S3. Applicant’s justification for changing current combination products from exempt or S2 to S3 is on theoretical basis only, and no evidence provided of clinical risk. Pharmacokinetic study found that co-administration of paracetamol with phenylephrine increased plasma phenylephrine levels - applicant says this has potential for cardiac safety risk in susceptible patients.
Athletes will greatly benefit from using Ipamorelin. For example, if you use CJC 1295 along with Ipamorelin, the results are going to be even greater. HGH increase will result in greater muscle mass levels, less time for muscle mass to develop, and increased levels of lean muscle tissue. The more peptides your body produces, the greater your lean muscle mass is going to be. And, over time, with gradual increases in HGH, you are going to realize a leaner, more muscular definition to your body.
Diets on point! 6 600 calorie meals totaling 200-300g protein, 50-150g carbs and almost NO fat. I do get a little fat in my diet from flax, trail mix and what not but all my food is natural, whole and as close to organic as I can get.. TONS of raw veggies. NO cardio atm, Ive got some bad injuries and issues developed from my last cycle so I take it pretty easy LOL. Maybe an hour on the bicycle 1-2x/wk.. Tough job tho so at work 8hrs a day working on diesel pile hammers keeps my heart rate pretty high all day
Increasing HGH release levels in your body naturally. It sounds too good to be true, but what if you could achieve just that by using a supplement? Using Ipamorelin alongside your exercise and diet regimen is going to help you achieve said goal. No two users are alike. For athletes or those who workout religiously, you might experience greater results than an individual who is overweight and just getting back into the gym after 10 years. So, take it with a grain of salt when detailing the results below. Dosage, your body composition, and other factors will play a role in the results you can expect to see when you incorporate Ipamorelin.
Phenylephrine is readily eliminated by sulphate conjugation in the intestinal wall, and oxidative deamination by monoamine oxidative glucuronidation in the liver. Monoamine oxidase (MAO) inhibitors can enhance the limited potential of phenylephrine for cardiac and pressor effects, by reducing metabolism. As a largely specific alpha adrenergic drug, with very weak beta agonism, there is little direct cardiac effect. However, in higher doses, there can be increases in both systolic and diastolic blood pressure and a reflex bradycardia. As an adrenergic agonist there is the potential to interact with other sympathomimetic drugs. In overdose phenylephrine can cause hypertension, headaches seizures tachycardia, and vomiting. There has been no evidence from carcinogenicity studies in rodents of any enhanced cancer risk over prolonged exposure.

Thirty-two rabbits were divided into 4 equal groups. Four different solutions, including saline, HA, AOD9604, and AOD9604 with HA, were injected in each group on a weekly basis for 4–7 weeks after the first collagenase injection. Group 1 received intra-articular saline injection (0.6 mL). Group 2 received intra-articular HA, (Hyruan-plus®; LG Life Science, Daejeon, Korea) injection (6 mg). The molecular weight of HA was measured at 3.0×106 Da, and it was prepared to a 10 mg/mL concentration. Group 3 received intra-articular AOD9604 (Metabolic pharmaceuticals, Melbourne, Australia) injection (0.25 mg per 0.6 mL). Group 4 received combined intra-articular AOD9604 (0.25 mg) and HA (6 mg) injections. All injections were administered by a physiatrist, using a commercially available ultrasound system with 3–12 MHz multi-frequency linear transducer (E-CUBE 15®; Alpionion Medical Systems, Seoul, Korea) under general anesthesia and under sterile conditions (Figure 1). No medication was administered after the injection. The rabbits were euthanized by CO inhalation 9 weeks after the first collagenase injection (Figure 2).


With a blend of peptide and GH supplements, Ipamorelin can greatly help you in your weight loss endeavours. Using it with IGF-1 which is a natural growth hormone, can help you achieve even greater results. With lower dosage, you won’t increase muscle mass, your body will naturally decrease body fat levels, and you will begin to metabolize food faster, meaning you burn more calories in less time, for greater weight loss results.


Following amplification, PCR products were electrophoresed on 1.3% agarose gels and transferred onto Hybond N+ membranes (RPN 303B, Amersham Pharmacia Biotech) by Southern blotting in 0.4 M NaOH/1 M NaCl. The membranes were rinsed for 5 min in 0.5 M Tris-HCl (pH 7.5)/1 M NaCl and then in 0.3 M NaCl/30 mM sodium citrate, and air dried. Membranes were apposed directly to a phosphor imager screen for 18 h, and scanned using a Storm PhosphorImager and data quantitated using MCID software (Imaging Research, Inc., St. Catherines, Ontario, Canada). The β3-AR product bands were normalized against the β-actin control, averaged, and RNA isolated from treated animals was expressed against control animals.
Both human GH (hGH) and a lipolytic fragment (AOD9604) synthesized from its C-terminus are capable of inducing weight loss and increasing lipolytic sensitivity following long-term treatment in mice. One mechanism by which this may occur is through an interaction with the beta-adrenergic pathway, particularly with the beta(3)-adrenergic receptors (beta(3)-AR). Here we describe how hGH and AOD9604 can reduce body weight and body fat in obese mice following 14 d of chronic ip administration. These results correlate with increases in the level of expression of beta(3)-AR RNA, the major lipolytic receptor found in fat cells. Importantly, both hGH and AOD9604 are capable of increasing the repressed levels of beta(3)-AR RNA in obese mice to levels comparable with those in lean mice. The importance of beta(3)-AR was verified when long-term treatment with hGH and AOD9604 in beta(3)-AR knock-out mice failed to produce the change in body weight and increase in lipolysis that was observed in wild-type control mice. However, in an acute experiment, AOD9604 was capable of increasing energy expenditure and fat oxidation in the beta(3)-AR knock-out mice. In conclusion, this study demonstrates that the lipolytic actions of both hGH and AOD9604 are not mediated directly through the beta(3)-AR although both compounds increase beta(3)-AR expression, which may subsequently contribute to enhanced lipolytic sensitivity.
But gene-therapy experiments have also resulted in patient deaths. The use of such therapies can cause the human body to experience fatal immune reactions to the vectors used to place the gene in the body. Another danger of gene therapy is an inability to control the expression of the gene, which could translate into a rapidly spreading cancer. Or the expression of the gene could spread from skeletal muscle into heart muscle, resulting in excessive heart muscle growth (known as left ventricular hypertrophy, or “athlete’s heart) that can cause premature heart failure.

It is well known that hGH is associated with increased IGF-1 levels. IGF-1 may have a variety of undesirable effects, including an increase in cancer risk [22, 23]. In the studies discussed herein, IGF-1 levels were monitored in all long-term studies but did not reveal clinically significant differences between dose groups or placebo. Therefore the 5 SAEs that occurred in the 12 week treatment study (three in the AOD9604 20 mg group (basal cell carcinoma, moderate lipoma and squamous cell carcinoma), one in the 10 mg group (malignant melanoma) and one in the 5 mg group (breast cancer)) could not be attributed to increased IGF-1 levels. The Principal Investigator considered none of the reported SAEs to be “possibly”, “probably” or “definitely related” to the study medication. The rationale behind this judgment was that none of the cancer forms occurred in the highest dosage group (30mg AOD9604/day), therefore a dose effect can be excluded. Further examination of the SAE cases indicated that these subjects had neglected their personal medical care for a longer period of time, so that the higher incidence of cancer may well have occurred due to the natural incidence rate of cancer events in the population.
The banned "peptide" believed to have been injected into numerous Australian professional athletes can be bought in under 30 seconds online. GHRP-6, the growth hormone-releasing peptide that features in the Australian Crime Commission's report into organised crime and drugs in sport released this morning, was identified -- alongside other so-called performance and image enhancing drugs (PIEDs) -- as a dubious supplement threatening to cast a pall over the country's professional codes. Although unproven, GHRP-6 purportedly helps the body repair damaged tissue and can stimulate human growth hormones to improve athletic performance. It can be used in conjunction with anabolic steroids to promote muscle gain. Peptides are classified as a prohibited substance on the World Anti-Doping Agency prohibited list and were banned for use both in and out of competition in 2008. The ACC report said most peptides are also:

For GH to exhibit its fat burning effects, insulin must NOT be present. Insulin release in the body is caused mainly by consuming carbohydrates, although all types of macronutrients (carbs, fat and protein) still cause the release of insulin to some extent. Since HGH Frag works by causing the body to break down and release stored fat for use as energy, if you have recently consumed calories (food or beverage) your body will just use that for energy instead and little extra fat will be burnt. If however there is no food present for the body to use as energy, it will use the stored fat which the HGH Frag has caused to be released and you will notice reductions in body fat over the ensuing weeks.
The nature of the response to both hGH and AOD9604 is not clearly understood. We hypothesized that both molecules may influence the expression of the β3-adrenergic receptors (β3-ARs), the major lipolytic receptor in fat tissue. Both AOD9604 and hGH can increase β3-AR mRNA expression, as well as protein levels and function, in mouse and human cell lines in vitro (11). This response was investigated at the level of RNA and protein expression and function. The results for each mode of analysis were consistent in that both hGH and AOD9604 acted in a dose- and time-dependent manner to modulate the β3-AR response.
The weight lost by the 1mg group was slightly more than that achieved by the world’s largest selling prescription obesity medication in similar trials over the same period, without its troublesome side effects. The trial results also demonstrated a small but consistent improvement in cholesterol profiles, and a reduction in the number of patients with impaired glucose tolerance.
Between 2001 and 2006 six human clinical trials with the hexadecapeptide AOD9604 have been performed, 893 healthy, in all but one study, clinically obese adults participated in these studies and are the basis of this safety evaluation. The details of the individual studies are listed in supplementary data. The first 3 studies were dose-escalating studies investigating the acute effects of various dosages and two application routes (i.v. and oral) in healthy or obese male subjects. These single dose studies were followed by a 7-day multiple dose study (METAOD004) as well as two long-term clinical trials (METAOD005 and METAOD006) where the safety and tolerability of chronic oral treatment with AOD9604 was investigated.
CJC-1295 is a fast-acting Growth Hormone Releasing Hormone designed to enhance the body’s natural production and release of human growth hormone and Insulin-like Growth Factor 1 (IGF-1). In doing so, CJC-1295 reverses the age-related decline, generates new muscle cells and increases fat loss. Another great trait of CJC-1295 is its ability to promote slow wave sleep, a deep sleep responsible for the highest levels of cell regeneration, muscle growth and memory retention.
These peptides are inhibitors of a protein called myostatin. Myostatin is secreted by muscle cells and acts to essentially block the development of new muscle fibers and, thus, the development of lean muscle mass. In fact, individuals who have mutations in the gene coding for this protein have significantly more muscle mass and enhanced strength. The administration of follastatin peptides can generate enhanced muscle mass and strength, and has been found especially useful in patients suffering from muscle-wasting diseases or who have difficulty gaining muscle.
The discovery of the role of Tβ4 in the process of immune regulation has lead to its use as a valuable therapeutic agent. Tβ4 has been used in the treatment of HIV, AIDS, Influenza, colds, and various infections. It has been utilized in the management of various inflammatory conditions, as well as part of treatment following heart attack due to its cardio and neuroprotective effects.
The final study involved an assessment of the acute effect of AOD9604 and a β3-AR agonist (BRL37344) on energy expenditure, fat oxidation, and glucose oxidation in WT andβ 3-KO mice. When AOD9604 or BRL37344 were administered to WT mice, an acute increase in fat oxidation and energy expenditure occurred, with an associated reduction in glucose oxidation (Fig. 6A). The effect plateaued 18 min following injection and remained stable for the duration of the experiment. The response to the two compounds was very similar, despite the fact we have previously shown that AOD9604 does not directly interact with the β3-AR as demonstrated by ligand binding studies (11). This clear separation of pathways was further confirmed in Fig. 6B in which AOD9604 clearly increases fat oxidation and energy expenditure inβ 3-KO mice, whereas BRL37344 does not. The KO mice neither decrease their glucose oxidation in response to AOD9604 nor show a prolonged increase in fat oxidation and energy expenditure in response to AOD9604.
Finally, patients deficient in growth hormone who get IGF-1 injections have shown increased rates of fat loss and fat oxidation. One theory for this is that, as you’ve just learned, IGF-1 can suppress circulating insulin, which would allow more burning of fatty acids from fat cells. This makes sense, since we do know that fat cells contain IGF-1 receptors, and this means that IGF-1 can interact with fat cells.
The peptide therapy protocols (Amino Acid Analogs) prescribed by TeleWellnessMD providers are also known as secretagogues (pronounced se-creta-gog), a substance that promotes secretion. These amino acid chains communicate with the body to produce or release growth hormone. Hence a secretagogue causes the body’s own natural processes to produce growth hormone. Secretagogues do not act as growth hormones but rather stimulate the pituitary gland to secrete your stored growth hormone. The subcutaneous injection route of growth hormone stimulation is a preferred route to help slow down age and environmental reductions in growth hormone levels.

Paracetamol/caffeine formulations have a long-established safety and efficacy profile over 25 years of use as an open-sale medicine in major markets around the world. The paracetamol/caffeine combination analgesic was registered as a schedule 2 product in Australia and has been marketed since 2010. Since that time no new significant issues or potential risks have been reported.


DX-7 pushes the boundaries of fast acting diet pills! This formula is designed as a powerful detox with a 7 day formula! As one of the most effective short term detox diet pills on the market, DX-7 helps those who may have put on a few winter pounds. With powerful detox ingredients, this formula will help those that are trying to kick off a new year’s goals or trying to reach specific weight loss goals with an extra kick!
Phenylephrine is a direct alpha-1 adrenergic agonist, with weak alpha-2 adrenergic agonist activity. It also has very weak beta-adrenergic effects, but at therapeutic doses there are no significant stimulating beta-1 adrenergic effects on the heart, or on the bronchial airways, or on peripheral blood vessels. This contrasts with pseudoephedrine, which has greater beta-adrenergic activity. The effect on the alpha-adrenergic receptors leads to local vasoconstriction and shrinking of mucous membranes. There is no anti-histamine effect. The drug is readily and completely absorbed following oral administration, undergoing extensive first pass metabolism in the intestinal wall and in the liver leading to some variability in individual pharmacokinetics. Nasal decongestion is apparent within 15 to 20 minutes and persists for up to 4 hours (AHFS 2007).

One proposed mechanism for reduced natriuretic peptide concentrations in obesity is the relative abundance of natriuretic peptide clearance receptors (NPR‐C) in adipose tissue.13, 22 Elevated insulin has also been linked to increased expression of NPR‐C in obese subjects.23 On the other hand, plasma Nt‐proANP and Nt‐proBNP levels are reduced in obesity to a comparable degree as the mature peptides. Because the pro‐peptides are not known to bind to NPR‐C, impaired synthesis or secretion likely plays a role in obesity.
The human growth hormone (hGH) is a 191-amino acid long, single-chain polypeptide secreted by the pituitary gland under the regulation of the hypothalamus. It regulates a variety of biological processes in various tissues. When binding to the hGH-receptor it activates one of various signaling cascades, depending on the tissue. In the liver hGH induces the secretion of Insulin-Like Growth Factor-1 (IGF-1). IGF-1 can stimulate growth in almost every tissue in the body, including skeletal muscle, cartilage, bone, liver, kidney, nerves etc. [1].
Another very positive benefit of CJC1295 is its ability to promote slow wave sleep. Slow wave sleep (SWS) is also known as deep sleep and is the portion of sleep responsible for the highest level of muscle growth and memory retention. SWS is decreased significantly in older adults and also with people who tend to exercise later in the evening.  This peptide has a benefit to side effect ratio that exceeds all others currently being legally sold and would make a great addition to ones training regimen or post cycle therapy.
An OGTT was performed at screening and after 12 and 24 weeks of treatment. At these visits blood samples for assessment of glucose and insulin were collected immediately prior to and 2 hours after an oral glucose load. After 12 weeks the overall change in pre-load glucose was -0.02 units and there were no significant differences between the randomized treatment groups (P = 0.73488). The changes in pre-load glucose in the placebo group differed by -0.08, -0.06, and -0.07 units from those obtained in the AOD9604 0.25 mg, 0.5 mg, and 1 mg treatment groups, respectively; none of these differences were statistically significant. Similar results have been obtained after 24 weeks of treatment. The overall change in pre-load glucose after 24 weeks treatment was 0.04 units, and there were no significant differences among the treatment groups (P = 0.62787). Estimated differences from placebo in change in pre-load glucose were -0.03, 0.02, and 0.06 units for the AOD9604 0.25 mg, 0.5 mg, and 1 mg treatment groups, respectively; none of these differences were statistically significant.
Bremelanotide PT 141 was developed from Melanotan II, targeting its aphrodisiac effects. This peptide has been shown to have a substantial effect on libido, generating sexual arousal in both men and women within minutes of administration. It has been shown to be effective in treating erectile dysfunction, even in men who have not responded to other ED treatments, such as Viagara. This peptide is also able to cross the blood-brain-barrier, bypassing the vascular system and acting at the level of the central nervous system. This property gives Bremelanotide an advantage over traditional ED drugs, which can decrease blood pressure to dangerous levels. This peptide can be administered as a nasal spray, making its use convenient and discreet.
If there was a magic pill that could help improve digestion and gut health, erase wrinkles, ease joint pain and give you healthy, thick hair and nails, I would buy it by the truckload. After all, while boosting my overall health is a priority, having shinier hair and minimal crow’s feet is a major bonus. Although there’s no such magic pill, there is a supplement that promises these results and more—collagen peptides.
People who are serious about losing weight or improving physical performance may choose to use some of the controversial peptides. They are generally sold for research purposes, but many injectable forms of peptides have been used by athletes to increase the production of their body’s HGH to achieve increased lean body mass, decreased body fat, and improved recovery time after workouts. Peptides used for these purposes include:
CJC 1295 has shown some amazing results as a growth hormone releasing hormone (GHRH) analog. Not only has CJC 1295 shown potential to increase growth hormone and IGF-I secretion and effects, but it has been able to do so in very large amounts. CJC 1295 Stimulates Growth Hormone Secretion, and will keep a steady increase of HGH and IGF-1 with no increase in prolactin, leading to fat loss, and increased protein synthesis thereby promoting growth.
Actually, it's under S0 because it is not approved for human use by any regulating authority anywhere. The S2 category is the one relating to mimicking effects of other compounds or GH. But you were right, the OP is fundamentally incorrect. The real reasons that Dank chose this compound to administer to Essendon players is still a mystery but we can be certain it wasn't paid for or administered for the fun of it.
Thymosin beta-4 (TB-4): A naturally occurring protein found in blood platelets, TB-4 plays a role in the repair and regeneration of injured tissues in the human body. It was first detected in the thymus, a gland that produces white blood cells. While it’s recently been used to treat horses and implicated in horse doping, it’s also found its way into bodybuilding circles. While there is no published evidence that TB-4 produces any benefit to athletes, it was added to the WADA banned substances list in 2011.
Diet Doc’s certified medical weight loss doctors can help you discover the benefits of Ipamorelin as part of a personalized medical weight loss plan. Getting started with a Diet Doc medical weight loss plan is easy – just call us or send us some information to schedule a virtual or phone evaluation with a doctor. We’ll build your personalized weight loss program and put your medication in the mail that same day, so you can start losing weight as soon as possible. Using Ipamorelin requires a baseline and semi-annual IGF1 lab test to ensure levels are low enough to begin treatment, and that they don’t become too high during treatment. Get started today!
The company which developed it, Metabolic Pharmaceuticals, did have a small early study done which showed a small amount of fat loss at 1 mg per day but not really any other dosing. Measured effect was less at higher doses. In total the company did at least six studies. According to the lead researcher of five of the studies, Dr Gary Wittert, results were uniformly negative.

The study subjects were brought back to the MGH CRC 6 months after gastric bypass surgery and underwent an identical saline infusion protocol. Subjects were excluded from completing the second saline challenge protocol if they had developed complications of gastric bypass surgery including significant peri‐operative complications (myocardial infarction, persistent atrial fibrillation, sepsis, or gastrointestinal bleeding requiring blood transfusion >2 units).

As a athlete, incorporating a growth hormone-like Ipamorelin is extremely beneficial. Not only in the development of lean muscle tissue and muscle mass, but also in the decreased recovery time you are going to experience after each workout. You can workout more, you can workout and lift harder, and you can increase your level of exertion at the gym to experience the greatest gains, as your body is going to heal much faster than it would without the growth hormone.
These peptides are inhibitors of a protein called myostatin. Myostatin is secreted by muscle cells and acts to essentially block the development of new muscle fibers and, thus, the development of lean muscle mass. In fact, individuals who have mutations in the gene coding for this protein have significantly more muscle mass and enhanced strength. The administration of follastatin peptides can generate enhanced muscle mass and strength, and has been found especially useful in patients suffering from muscle-wasting diseases or who have difficulty gaining muscle.
Acromegaly is characterized by an excessive amount of articular cartilage in joints caused by excess GH secretion [25]. The tremendously thick articular cartilage in acromegaly can be explained by the local production of IGF-1 in cartilage cells through GH receptors [9,18]. Long-term treatment with GH might induce hypertrophy of the cartilage and changes in the joint geometry because of altered subchondral bone structures. Long-term treatment with GH by local injections may also be associated with various risks, including glucose intolerance, insulin resistance, diabetes, cancer, edema, and hypertension [26–29]. AOD9604 is not an agonist with a high affinity to the GH receptor and does not stimulate the production of IGF-1. Therefore, AOD9604 may be safer than human recombinant GH for the long-term treatment of OA.

The most potent weight loss peptide is HGH Fragment 176-191 which is the part of the Growth Hormone molecule responsible for fat burning. In HGH Frag Studies, it has been proven to reduce body fat, particularly in the abdominal area. The second most potent fat loss peptide is CJC-1295 DAC since it causes the overall GH level to rise in the body (the opposite of what happens naturally as a person gets older, which is why people tend to put on weight as they age). If your only goal is fat loss, it's often best to avoid the use of GHRP products (GHRP-6, GHRP-2 or Ipamorelin) since they can stimulate hunger and/or raise cortisol, both of which can be counterproductive to fat burning.


For Growth Hormone (GH) to perform its anabolic (muscle building) affects it requires the presence of the body's most anabolic hormone: insulin. This is in contrast to GH related fat loss which requires insulin to be absent. However, since GHRP and fast-acting GHRH (Growth Hormone Releasing Hormone) products (i.e. Modified GRF 1-29) still need time to stimulate the body to release GH from the pituitary gland, the insulin spike must come after the injection and not before, otherwise the GH release will be blunted.
For example, if 100mcg more were to be administered after the first 100mcg (making the effective dose of 200mcg), then the second dose will achieve only 50% of what the first dose already did. A 100mcg more (making a total of 300mcg) will achieve only 25% more of the initial dose. This implies that, in order to increase the effect of the compound, only a little more of it can be successfully administered after the saturation dose.
In total 118 AEs were reported. No SAEs were reported. The most common adverse event reported by 16/23 subjects (69.6%) was mild or moderate headache. From all the reported AEs three events were reported of severe intensity (one in the 50 µg/kg AOD9604 group, 2 in the placebo group), with one of those events (a feeling of chest tightness) deemed possibly related to the AOD9604 treatment. Mild or moderate euphoria deemed possibly related to treatment, was reported by 5/23 subjects, during the periods when the AOD9604 was administered. There were no reports of euphoria during placebo administration. In total, there was no observable trend between the different treatment groups with respect to the incidence of certain AEs.
Because these peptides are so numerous and variable in structure, their effects are likewise varied and wide-ranging. One class of these peptides are known as growth hormone secretagogues, and cause the secretion of one’s own, natural hGH in the body. These peptides have been shown to be very useful in the treatment of age-related conditions, osteoporosis, obesity, and various chronic inflammatory diseases, and have several advantages over traditional hGH administration.
The ACMS recommended that Growth Hormone Releasing Hormones (GHRHs), Growth Hormone Secretagogues (GHSs), Growth Hormone Releasing Peptides (GHRPs) as well as new individual substance entries for CJC-1295, ipamorelin, pralmorelin (Growth Hormone Releasing Peptide-2), Growth Hormone Releasing Peptide-6, hexarelin and AOD-9604 be included in Schedule 4.
Meanwhile, more Phase II clinical studies are planned for the next 12 months including a study examining the efficacy of oral administration, which has been shown to be effective in laboratory animals. This will be followed by a weight loss study. Confirmation of the age-effect will also be sought. Metabolic aims to start a two-year Phase III studies program in 2003, which would not place final FDA approval before 2005.

Specifically, T α 1 has been shown to enhance the function of certain immune cells called T and dendritic cells. This is very important to anyone with a depressed immune system or suffering from an infection, as these white blood cells play pivotal roles in the body’s defense process. T cells, for example, come in two forms: killer and helper T cells. Killer T cells are responsible for hunting down and destroying our body’s own cells that are cancerous or infected with bacteria or viruses. Helper cells work with the other cells of the immune system to orchestrate and carry out appropriate immune responses.


No need to visit a physical peptide clinic, Muscle Peptide Australia can ship throughout Australia: to Sydney, Melbourne, Brisbane, Perth, Adelaide, Darwin, Hobart and regional areas. There’s no time like now to begin this journey. Customers can order from our convenient and user-friendly website to get the supplements they need. Send us an e-mail, and our customer service team will be happy to address any questions or concerns you may have. We specialize in offering an affordable and efficient way to stay healthy for good.
×